The Androgenetic Alopecia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Androgenetic Alopecia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Androgenetic Alopecia Market.
Some of the key takeaways from the Androgenetic Alopecia Pipeline Report:
- Companies across the globe are diligently working toward developing novel Androgenetic Alopecia treatment therapies with a considerable amount of success over the years.
- Androgenetic Alopecia companies working in the treatment market are OliX Pharmaceuticals, Carmell therapeutics, Cutia Therapeutics, Follicle Pharma, Dermaliq Therapeutics, Merz Aesthetics Inc., Cosmo Pharmaceuticals, Kintor Pharmaceuticals, and others, are developing therapies for the Androgenetic Alopecia treatment
- Emerging Androgenetic Alopecia therapies in the different phases of clinical trials are- OLX104C, Tissue healing accelerant, CU 40101-101, FOL100, DLQ01, Incobotulinumto xin A, Breezula, KX-826, and others are expected to have a significant impact on the Androgenetic Alopecia market in the coming years.
- In January 2022, Kintor Pharmaceuticals started a phase II, randomised, double-blind, placebo-controlled, parallel group trial to assess KX-826’s safety, tolerability, and effectiveness in male individuals suffering from androgenetic alopecia.
- In August 2021, The favorable outcomes of Phase 2b 3 ALLEGRO, which assessed an oral once-daily Ritlecitinib medication in patients with alopecia areata—an autoimmune illness that causes hair loss on the scalp and can also affect the face and body—were revealed by Pfizer Inc.
- In March 2020, indication for the management of the autoimmune condition known as Alopecia Treatment Areata (AA). Drugs meant to treat serious conditions are to be reviewed and developed more quickly after being designated as Breakthrough Therapy.
Androgenetic Alopecia Overview
Both men and women can suffer from androgenetic alopecia, which is a non-scarring alopecia. In genetically predisposed men and women, it is typified by a progressive shrinkage of hair follicles with a distinctive pattern distribution.is the most common kind of hair loss that affects both genders.
Get a Free Sample PDF Report to know more about Androgenetic Alopecia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/androgenetic-alopecia-pipeline-insight
Emerging Androgenetic Alopecia Drugs Under Different Phases of Clinical Development Include:
- OLX104C: OliX Pharmaceuticals
- Tissue healing accelerant: Carmell therapeutics
- CU 40101-101: Cutia Therapeutics
- FOL100: Follicle Pharma
- DLQ01: Dermaliq Therapeutics
- Incobotulinumto xin A: Merz Aesthetics Inc.
- Breezula: Cosmo Pharmaceuticals
- KX-826: Kintor Pharmaceuticals
Androgenetic Alopecia Route of Administration
Androgenetic Alopecia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Androgenetic Alopecia Molecule Type
Androgenetic Alopecia Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Androgenetic Alopecia Pipeline Therapeutics Assessment
- Androgenetic Alopecia Assessment by Product Type
- Androgenetic Alopecia By Stage and Product Type
- Androgenetic Alopecia Assessment by Route of Administration
- Androgenetic Alopecia By Stage and Route of Administration
- Androgenetic Alopecia Assessment by Molecule Type
- Androgenetic Alopecia by Stage and Molecule Type
DelveInsight’s Androgenetic Alopecia Report covers around 12+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Androgenetic Alopecia product details are provided in the report. Download the Androgenetic Alopecia pipeline report to learn more about the emerging Androgenetic Alopecia therapies
Some of the key companies in the Androgenetic Alopecia Therapeutics Market include:
Key companies developing therapies for Androgenetic Alopecia are – Concert Pharmaceuticals, Pfizer, Legacy Healthcare, Horizon Therapeutics, Reistone Biopharma, and others.
Androgenetic Alopecia Pipeline Analysis:
The Androgenetic Alopecia pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Androgenetic Alopecia with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Androgenetic Alopecia Treatment.
- Androgenetic Alopecia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Androgenetic Alopecia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Androgenetic Alopecia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Androgenetic Alopecia drugs and therapies
Androgenetic Alopecia Pipeline Market Drivers
- Growing prevalence of hair loss, increase in the number of research and development activities are some of the important factors that are fueling the Androgenetic Alopecia Market.
Androgenetic Alopecia Pipeline Market Barriers
- However, adverse side-effects of medication, high cost of medications and other factors are creating obstacles in the Androgenetic Alopecia Market growth.
Scope of Androgenetic Alopecia Pipeline Drug Insight
- Coverage: Global
- Key Androgenetic Alopecia Companies: OliX Pharmaceuticals, Carmell therapeutics, Cutia Therapeutics, Follicle Pharma, Dermaliq Therapeutics, Merz Aesthetics Inc., Cosmo Pharmaceuticals, Kintor Pharmaceuticals, and others
- Key Androgenetic Alopecia Therapies: OLX104C, Tissue healing accelerant, CU 40101-101, FOL100, DLQ01, Incobotulinumto xin A, Breezula, KX-826, and others
- Androgenetic Alopecia Therapeutic Assessment: Androgenetic Alopecia current marketed and Androgenetic Alopecia emerging therapies
- Androgenetic Alopecia Market Dynamics: Androgenetic Alopecia market drivers and Androgenetic Alopecia market barriers
Request for Sample PDF Report for Androgenetic Alopecia Pipeline Assessment and clinical trials
Table of Contents
1. Androgenetic Alopecia Report Introduction
2. Androgenetic Alopecia Executive Summary
3. Androgenetic Alopecia Overview
4. Androgenetic Alopecia- Analytical Perspective In-depth Commercial Assessment
5. Androgenetic Alopecia Pipeline Therapeutics
6. Androgenetic Alopecia Late Stage Products (Phase II/III)
7. Androgenetic Alopecia Mid Stage Products (Phase II)
8. Androgenetic Alopecia Early Stage Products (Phase I)
9. Androgenetic Alopecia Preclinical Stage Products
10. Androgenetic Alopecia Therapeutics Assessment
11. Androgenetic Alopecia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Androgenetic Alopecia Key Companies
14. Androgenetic Alopecia Key Products
15. Androgenetic Alopecia Unmet Needs
16 . Androgenetic Alopecia Market Drivers and Barriers
17. Androgenetic Alopecia Future Perspectives and Conclusion
18. Androgenetic Alopecia Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services